Get the Stockscreener App
7.30
3.18%
-0.24
After Hours:
7.29
-0.010
-0.14%
Vyome Holdings Inc stock is traded at $7.30, with a volume of 30,949.
It is down -3.18% in the last 24 hours and up +0.00% over the past month.
Vyome Holdings Inc is a clinical stage specialty pharmaceutical company working to treat immuno-inflammatory diseases including rare indications of unmet need with next-generation therapeutic solutions.
See More
Previous Close:
$7.54
Open:
$7.33
24h Volume:
30,949
Relative Volume:
1.46
Market Cap:
$212.00M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-8.18%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$7.11
$7.7654
1-Week Range:
$7.11
$8.46
52-Week Range:
$7.11
$12.87
Vyome Holdings Inc Stock (HIND) Company Profile
Name
Vyome Holdings Inc
Sector
Industry
Phone
949-429-6680
Address
1001 CALLE AMANECER, SAN CLEMENTE
Compare HIND with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HIND
Vyome Holdings Inc
|
7.30 | 212.00M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Vyome Holdings Inc Stock (HIND) Latest News
Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies - PharmiWeb.com
Vyome Holdings strengthens leadership team with industry veterans as it plans pivotal trial studies - MarketScreener
Vyome Holdings, Inc. Announces Executive Changes - MarketScreener
Vyome Holdings Completes Merger with Vyome Therapeutics - MSN
Vyome Holdings Announces Positive Interim Data from Phase 2 Study of VT-1953 in Malignant Fungating Wounds (MFW) and Provides Update on MFW market opportunity - biospace.com
Vyome Holdings Inc positive interim data from Phase 2 Study of VT-1953 in malignant fungating wounds - MarketScreener
Vyome’s VT-1953 shows significant reduction in cancer wound odor By Investing.com - Investing.com Australia
Vyome’s VT-1953 shows significant reduction in cancer wound odor - Investing.com
Vyome Holdings completes merger with Vyome Therapeutics and files financials By Investing.com - Investing.com UK
Vyome Holdings completes merger with Vyome Therapeutics and files financials - Investing.com
Vyome Holdings, Embryyo Technologies Partner on AI Medtech - Medical Product Outsourcing
Vyome, Embryyo form partnership to pursue AI-enabled medical devices - Medical Economics
US-based Vyome signs MoU with India’s leading medical device innovation studio Embryyo - BioSpectrum India
Vyome And Embryyo Sign MoU To Develop AI-Enabled Medical Devices - Sahyadri Startups
Vyome Holdings, Inc. Signs MoU with Embryyo Technologies - MarketScreener
Vyome, India's Embryyo Sign MOU to Pursue AI Medical Device Market; Shares up Pre-Bell - MarketScreener
Vyome partners with Embryyo to enter AI-enabled medical device market - Investing.com
Vyome Signs MoU with Embryyo, India’s Leading Medical Device Innovation Studio - FinancialContent
Vyome Holdings expands at-the-market offering and appoints new auditor - Investing.com India
Vyome Holdings expands at-the-market offering and appoints new auditor By Investing.com - Investing.com South Africa
Vyome Holdings Amends Equity Distribution Agreement - TipRanks
Vyome Amends Equity Distribution Agreement with ReShape Lifesciences Inc. - AInvest
Vyome enters amendment no. 1 to equity distribution agreement - MarketScreener
Vyome to review strategic options for majority-owned Livechain By Investing.com - Investing.com Australia
Vyome to review strategic options for majority-owned Livechain - Investing.com
ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update - MarketScreener
Vyome Debuts as HIND on Nasdaq, Strengthening US-India Innovation Ties - YourStory.com
ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update - MarketScreener
Vyome lists on Nasdaq as HIND after ReShape merger - The Times of India
HIND Stock Price and Chart — NASDAQ:HIND - TradingView
Vyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HIND - MarketScreener
Vyome Therapeutics Completes Merger With ReShape Lifesciences - MarketScreener
Vyome to leverage US-India ties to tackle $100B immuno-inflammatory market - Investing.com Canada
Vyome to begin trading as Vyome Holdings under HIND symbol By Investing.com - Investing.com Australia
Health Care Stocks Climb As Deals And Results Grab Attention - Finimize
Breaking: Clinical-Stage Biotech Vyome Finalizes ReShape Merger, Set for Nasdaq Debut as HIND Tomorrow - Stock Titan
ReShape Lifesciences Stock Rocketed 37% Today – Here’s Why By Stocktwits - Investing.com India
Vyome announces Nasdaq approval of merger with ReShape Lifesciences - TipRanks
Vyome therapeutics to list on nasdaq as HIND after reshape merger - Investing.com Canada
ReShape Lifesciences Stock Rocketed 37% Today – Here’s Why - Asianet Newsable
Vyome to replace ReShape leadership as it prepares for Nasdaq listing - Investing.com Canada
Vyome to replace ReShape leadership as it prepares for Nasdaq listing By Investing.com - Investing.com South Africa
Vyome Announces New Board of Directors with Deep MIT and AI Ties - FinancialContent
ReShape Lifesciences Approves Asset Sale and Merger with Vyome Therapeutics - AInvest
ReShape Shareholders Approve Vyome Merger, Shares to Commence Trading on Nasdaq as Vyome Holdings, Inc. - AInvest
ReShape Lifesciences Announces Shareholder Approval of Merger with Vyome Therapeutics - Business Wire
ReShape Lifesciences Merger at Critical Stage: Stockholders Must Approve Asset Sale by August 7 - Stock Titan
ReShape Lifesciences Strategic Transformation: Board and Proxy Advisors Unite Behind Vyome Merger - Stock Titan
AUTOCANADA ANNOUNCES CONFERENCE CALL AND WEBCAST DETAILS FOR Q2 2025 FINANCIAL RESULTS - The Globe and Mail
ReShape Lifesciences Slashes Payroll by 23.4% While Fast-Tracking Vyome MergerKey Details Revealed - Stock Titan
ReShape Lifesciences Stock Soars On Distribution Agreement With Recon Supply, Draws Retail Applause By Stocktwits - Investing.com India
Vyome Holdings Inc Stock (HIND) Financials Data
There is no financial data for Vyome Holdings Inc (HIND). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):